{"nctId":"NCT01294423","briefTitle":"Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2011-02"},"conditions":["Type 2 Diabetes","High Blood Sugar"],"count":261,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* Men or women age ≥20 years old (Either gender needs to be 40% or higher of total number of treated subjects)diagnosed with type 2 DM ; ≥6.5% and ≤10% at 1 week before randomization\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* FPG \\>240 mg/dL before randomization\n* Subjects who have history of unstable or rapidly progressing renal disease\n* Subjects who have severe hepatic insufficiency and/or significant abnormal liver function\n* Significant cardiovascular history","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To compare change from baseline in HbA1c achieved with each dose of dapagliflozin versus placebo after 24 weeks double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":null},{"groupId":"OG001","value":"-0.45","spread":null},{"groupId":"OG002","value":"-0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG)","description":"To compare the change from baseline in fasting plasma glucose (FPG) achieved with each dose of dapagliflozin versus placebo after 24 weeks double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":null},{"groupId":"OG001","value":"-13.7","spread":null},{"groupId":"OG002","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight","description":"To compare the change from baseline in total body weight achieved with each dose of dapagliflozin versus placebo after 24 weeks double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.13","spread":null},{"groupId":"OG001","value":"-2.22","spread":null},{"groupId":"OG002","value":"-0.84","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":86},"commonTop":["NASOPHARYNGITIS","HYPERTENSION"]}}}